BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Falter T, Herold S, Weyer-Elberich V, Scheiner C, Schmitt V, von Auer C, Messmer X, Wild P, Lackner KJ, Lämmle B, Scharrer I. Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab. Thromb Haemost 2018;118:1743-51. [PMID: 30235478 DOI: 10.1055/s-0038-1668545] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Subhan M, Scully M. Advances in the management of TTP. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kubo M, Sakai K, Yoshii Y, Hayakawa M, Matsumoto M. Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan. Int J Hematol 2020;112:764-72. [PMID: 32856231 DOI: 10.1007/s12185-020-02974-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Goshua G, Sinha P, Hendrickson JE, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021;137:969-76. [PMID: 33280030 DOI: 10.1182/blood.2020006052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
4 Goshua G, Gokhale A, Hendrickson JE, Tormey C, Lee AI. Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura. Blood Adv 2020;4:539-45. [PMID: 32045473 DOI: 10.1182/bloodadvances.2019000827] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Pavenski K, Huang SS, Patriquin CJ. Predictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpura. Expert Rev Hematol 2021;:1-14. [PMID: 34747320 DOI: 10.1080/17474086.2021.2003703] [Reference Citation Analysis]
6 Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost 2020;18:2486-95. [PMID: 32914582 DOI: 10.1111/jth.15006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
7 Owattanapanich W, Wongprasert C, Rotchanapanya W, Owattanapanich N, Ruchutrakool T. Comparison of the Long-Term Remission of Rituximab and Conventional Treatment for Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost 2019;25:1076029618825309. [PMID: 30808221 DOI: 10.1177/1076029618825309] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
8 Sun L, Mack J, Li A, Ryu J, Upadhyay VA, Uhl L, Kaufman RM, Stowell CP, Dzik WS, Makar RS, Bendapudi PK. Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. Blood Adv 2019;3:1512-8. [PMID: 31076407 DOI: 10.1182/bloodadvances.2019031039] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
9 Li A, Kremer Hovinga JA. Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2020;2020:82-4. [PMID: 33275690 DOI: 10.1182/hematology.2020000164] [Reference Citation Analysis]
10 Uchino K, Sakai K, Shinohara S, Matsuhisa A, Iida Y, Nakano Y, Matsumura S, Kanasugi J, Takasugi S, Nakamura A, Horio T, Murakami S, Mizuno S, Yamamoto H, Hanamura I, Matsumoto M, Takami A. Successful preventive treatment with cyclosporine in a patient with relapsed/refractory immune-mediated thrombotic thrombocytopenic purpura: a case report and review of the literature. Int J Hematol 2022. [PMID: 35274194 DOI: 10.1007/s12185-022-03319-7] [Reference Citation Analysis]
11 Sukumar S, Lämmle B, Cataland SR. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med 2021;10:536. [PMID: 33540569 DOI: 10.3390/jcm10030536] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
12 Tiscia G, Sartori MT, Giuffrida G, Ostuni A, Cascavilla N, Nicolosi D, Battista C, Santeramo TM, Melillo L, Giordano G, Cappucci F, Fischetti L, Chinni E, Tarantini G, Cerbo A, Bertomoro A, Fabris F, Grandone E. Focus on Key Issues in Immune Thrombotic Thrombocytopenic Purpura: Italian Experience of Six Centers. J Clin Med 2021;10:5702. [PMID: 34884404 DOI: 10.3390/jcm10235702] [Reference Citation Analysis]
13 Fodil S, Zafrani L. Severe Thrombotic Thrombocytopenic Purpura (TTP) with Organ Failure in Critically Ill Patients. JCM 2022;11:1103. [DOI: 10.3390/jcm11041103] [Reference Citation Analysis]
14 Gómez-Seguí I, Pascual Izquierdo C, de la Rubia Comos J. Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura. Expert Rev Hematol 2021;14:707-19. [PMID: 34275393 DOI: 10.1080/17474086.2021.1956898] [Reference Citation Analysis]